
Individual Patient Expanded Access Applications: Form FDA 3926

Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (CDER) Larry Lim, 301-796-3146; or (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-7800.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**February 2015
Procedural**

Individual Patient Expanded Access Applications: Form FDA 3926 Guidance for Industry

Additional copies are available from:

*Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov*

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

or

*Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993
Phone: 800-835-4709 or 240-402-7800
Email: ocod@fda.hhs.gov*

<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**February 2015
Procedural**

Contains Nonbinding Recommendations

Draft — Not for Implementation

TABLE OF CONTENTS

- I. INTRODUCTION..... 1**
- II. BACKGROUND 2**
 - A. Expanded Access for an Individual Patient..... 2**
 - B. Emergency Expanded Access for an Individual Patient 4**
- III. OVERVIEW OF DRAFT FORM FDA 3926 4**
- APPENDIX 1: DRAFT FORM FDA 3926 7**

1 **Individual Patient Expanded Access Applications:**
2 **Form FDA 3926**
3 **Guidance for Industry¹**
4

5
6 This draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current
7 thinking on this topic. It does not create or confer any rights for or on any person and does not operate to
8 bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of
9 the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA
10 staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call
11 the appropriate number listed on the title page of this guidance.
12

13
14
15
16 **I. INTRODUCTION**
17

18 This guidance introduces and describes draft Form FDA 3926 (Individual Patient Expanded
19 Access—Investigational New Drug Application (IND)). When finalized, draft Form FDA 3926
20 will be available for licensed physicians to use for expanded access requests for individual
21 patient INDs. Expanded access requests are sometimes referred to as *compassionate use*
22 requests. Individual patient expanded access allows for the use of an investigational drug outside
23 of a clinical investigation for an individual patient who has a serious or immediately life-
24 threatening disease or condition and there is no comparable or satisfactory alternative therapy to
25 diagnose, monitor, or treat the disease or condition. When finalized, draft Form FDA 3926 is
26 intended to provide a streamlined alternative for submitting an investigational new drug
27 application (IND) under § 312.23 for use in cases of individual patient expanded access. This
28 draft guidance and draft Form FDA 3926 are not intended to apply to other types of expanded
29 access requests, including requests for expanded access for medical devices.
30

31 FDA’s guidance documents, including this guidance, do not establish legally enforceable
32 responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should
33 be viewed only as recommendations, unless specific regulatory or statutory requirements are
34 cited. The use of the word *should* in Agency guidances means that something is suggested or
35 recommended, but not required.
36
37

¹ This guidance has been prepared by the Office of the Commissioner, Office of Policy, Planning, Legislation and Analysis, in cooperation with the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.

Contains Nonbinding Recommendations

Draft — Not for Implementation

38 **II. BACKGROUND**

39
40 On August 13, 2009, FDA published a final rule (74 FR 40900) to amend its IND regulations by
41 removing certain sections of 21 CFR part 312 on treatment use of investigational drugs and
42 adding subpart I of part 312 (21 CFR part 312, subpart I) on expanded access. Subpart I
43 describes the following ways that patients may gain access to investigational drugs through
44 expanded access:

- 45
- 46 • Expanded access for individual patients, including for emergency use;
- 47
- 48 • Expanded access for intermediate-size patient populations (smaller than those typical of a
49 treatment IND or treatment protocol); and
- 50
- 51 • Expanded access for widespread treatment use through a treatment IND or treatment
52 protocol (designed for use in larger patient populations).
- 53

54 The final rule was, among other things, intended to increase awareness and knowledge of
55 expanded access programs and the procedures for obtaining investigational drugs for treatment
56 use for patients with serious or immediately life-threatening diseases or conditions who lack
57 therapeutic alternatives. It was also intended to facilitate the availability, when appropriate, of
58 investigational new drugs for treatment use, while protecting patient safety and avoiding
59 interference with the development of investigational drugs for marketing under approved
60 applications.

61 62 **A. Expanded Access for an Individual Patient**

63
64 FDA may permit expanded access to an investigational new drug for an individual patient when
65 the applicable criteria in 21 CFR 312.305(a) (which applies to all types of expanded access) and
66 21 CFR 312.310(a) (which applies specifically to individual patient expanded access, including
67 in an emergency) are met. Under the applicable criteria in 21 CFR 312.305(a), FDA must
68 determine that:

- 69
- 70 • The patient to be treated has a serious or immediately life-threatening disease or
71 condition, and there is no comparable or satisfactory alternative therapy to diagnose,
72 monitor, or treat the disease or condition;
- 73
- 74 • The potential patient benefit justifies the potential risks of the treatment use and those
75 potential risks are not unreasonable in the context of the disease or condition to be
76 treated; and
- 77
- 78 • Providing the investigational drug for the requested use will not interfere with the
79 initiation, conduct, or completion of clinical investigations that could support marketing
80 approval of the expanded access use or otherwise compromise the potential development
81 of the expanded access use.

Contains Nonbinding Recommendations

Draft — Not for Implementation

82
83 Under the applicable criteria in 21 CFR 312.310(a):

- 84
- 85 • The physician must determine that the probable risk to the person from the
 - 86 investigational drug is not greater than the probable risk from the disease or condition;
 - 87 and
 - 88
 - 89 • FDA must determine that the patient cannot obtain the investigational drug under another
 - 90 IND or protocol.
- 91

92 For further information regarding those determinations, please see the draft guidance for industry
93 *Expanded Access to Investigational Drugs for Treatment Use – Qs & As.*² In addition,
94 § 312.305(b)(2) of FDA’s expanded access regulations sets forth the submission requirements
95 for all types of expanded access requests. Section 312.310(b) contains additional submission
96 requirements for individual patient expanded access requests. The physician may satisfy some of
97 the submission requirements by referring to information in an existing IND, ordinarily one held
98 by the manufacturer, if the physician obtains permission from that IND holder. If permission is
99 obtained, the physician should then provide to FDA a letter of authorization (LOA) from the
100 existing IND holder that permits FDA to reference that IND.

101
102 One of the requirements under § 312.305(b)(2) is that a “cover sheet” must be included “meeting
103 the requirements of § 312.23(a).” This provision applies to several types of submissions under
104 part 312, ranging from commercial INDs under § 312.23 that involve large groups of patients
105 enrolled in clinical trials to requests from licensed physicians to use an investigational drug for
106 an individual patient. FDA is concerned that physicians requesting expanded access for an
107 individual patient may have encountered difficulty in completing Form FDA 1571 (currently
108 used by sponsors for all types of IND submissions) and the associated documents, because it is
109 not tailored to requests for individual patient expanded access.

110
111 In an effort to streamline the submission process for individual patient expanded access INDs,
112 FDA intends to make draft Form FDA 3926 (Appendix 1) available, when finalized, for licensed
113 physicians to use to request expanded access to an investigational drug outside of a clinical trial
114 for an individual patient who has a serious or immediately life-threatening disease or condition
115 and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the
116 disease or condition (i.e., for individual patient expanded access, including in emergencies).
117 FDA generally intends to accept submission of draft Form FDA 3926, when finalized, to comply

² This guidance (*Individual Patient Expanded Access Applications: Form FDA 3926*) is intended to address the submission of draft Form FDA 3926, when finalized, for an individual patient expanded access IND submitted by a sponsor-investigator. For information on expanded access in general, including submitting an expanded access protocol to an existing IND, see FDA’s draft guidance for industry *Expanded Access to Investigational Drugs for Treatment Use — Qs and As*. When final, this guidance will represent FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA Drugs guidance Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>.

Contains Nonbinding Recommendations

Draft — Not for Implementation

118 with the IND submission requirements in §§ 312.23, 312.305(b), and 312.310(b). To the extent
119 that information required under part 312 is not contained in draft Form FDA 3926, FDA intends
120 to consider the submission of that form, when finalized, with the box in item 7 checked and the
121 form signed by the physician, to constitute a request under § 312.10 to waive any other
122 applicable application requirements, including additional information included in Form FDA
123 1571 and Form FDA 1572 (Statement of Investigator, which provides the identity and
124 qualifications of the investigator conducting the clinical investigation). Although FDA intends
125 to accept draft Form FDA 3926, when finalized, for submitting a new expanded access IND for a
126 single patient, the IND holder (physician) should use Form FDA 1571 for subsequent
127 submissions to his/her IND.

128

B. Emergency Expanded Access for an Individual Patient

129

130
131 In an emergency situation that requires the patient to be treated before a written submission can
132 be made, the request to use the investigational drug for individual patient expanded access may
133 be made by telephone (or other rapid means of communication) to the appropriate FDA review
134 division. Authorization of the emergency use may be given by an FDA official over the
135 telephone, provided the physician explains how the expanded access use will meet the
136 requirements of §§ 312.305 and 312.310 and agrees to submit an expanded access submission
137 within 15 working days of FDA's initial authorization of the expanded access use (§ 312.310(d)).
138

139

III. OVERVIEW OF DRAFT FORM FDA 3926

140

141 When a licensed physician would like to obtain an investigational drug for an individual patient,
142 the physician should first ensure that the manufacturer of the investigational drug is willing to
143 provide the drug. If the manufacturer agrees to provide the drug, the manufacturer should
144 provide the physician with a letter of authorization (LOA) that permits FDA to refer to
145 information the manufacturer has submitted to FDA (e.g., in a commercial IND), if applicable.
146 The physician should then submit an individual patient expanded access IND application to the
147 appropriate FDA review division and may choose to use draft Form FDA 3926 (Appendix 1),
148 when finalized, to do so.

149

150 Under individual patient expanded access INDs, the physician is considered a sponsor-
151 investigator and is responsible for complying with the responsibilities for sponsors and
152 investigators, including submitting IND safety reports and annual reports and maintaining
153 adequate drug disposition records. The responsibilities of sponsors and investigators are
154 described in subpart D of part 312 (21 CFR part 312, subpart D) and, for example, in the
155 guidance for industry *Investigator Responsibilities—Protecting the Rights, Safety, and Welfare of*
156 *Study Subjects*.³

157

158 The informed consent requirements in part 50 (21 CFR part 50) apply to treatment provided to
159 patients under expanded access INDs and protocols, and informed consent must be obtained

³ This guidance is available at <http://www.fda.gov/Drugs/default.htm>, under Guidances (Drugs).

Contains Nonbinding Recommendations

Draft — Not for Implementation

160 before initiating treatment, including in the case of emergency use, unless one of the exceptions
161 found in part 50 applies.⁴ Additionally, the institutional review board (IRB) requirements found
162 in 21 CFR part 56 apply (see 21 CFR 312.305(c)(4)), and IRB approval must be obtained before
163 starting treatment under an expanded access IND unless it is for emergency use (in which case
164 the IRB must be notified of the emergency treatment within 5 working days of treatment).⁵

165

166 Draft Form FDA 3926 includes the following information:

167

168 Box 1: *Patient's initials* (not the full name, to preserve confidentiality) and *date of*
169 *submission*.

170

171 Box 2: *Clinical information*, including indication, brief clinical history of the patient
172 (age, gender, weight, allergies, diagnosis, prior therapy, response to prior therapy), and
173 the rationale for requesting the proposed treatment, including an explanation of why the
174 patient lacks other therapeutic options.

175

176 Box 3: *Treatment information*, including the investigational drug's name and treatment
177 plan. This includes the planned dose, route and schedule of administration, planned
178 duration of treatment, monitoring procedures, and planned modifications to the treatment
179 plan in the event of toxicity.

180

181 Box 4: *Letter of authorization (LOA)* obtained from the investigational drug's
182 manufacturer and attached to draft Form FDA 3926, when finalized. An LOA grants
183 FDA the right to reference the application for information to satisfy submission
184 requirements, such as a description of the manufacturing facility, chemistry,
185 manufacturing and controls information, and pharmacology and toxicology information.
186 It should include the manufacturer's IND number. In cases where the manufacturer does

⁴ For information on informed consent in general, see FDA's draft guidance for industry *Informed Consent Information Sheet – Guidance for IRBs, Clinical Investigators, and Sponsors*. When final, this guidance will represent FDA's current thinking on this topic. For additional information on the part 50 informed consent exceptions, see the guidance for institutional review boards, clinical investigators, and sponsors *Exception from Informed Consent Requirements for Emergency Research*.

⁵ An IRB means any board, committee, or other group formally designated by an institution to review, to approve the initiation of, and to conduct periodic review of biomedical research involving human subjects. The primary purpose of IRB review is to assure that the rights and welfare of human subjects are protected, including by determining that informed consent is obtained in accordance with and to the extent required by Federal requirements. In most situations in which patients receive treatment under an expanded access IND, IRB review and approval must be obtained before initiating the treatment. Many institutions have their own IRB to oversee human subjects research conducted within the institution or by the staff of the institution. If the physician does not have access to a local IRB, an independent IRB may be used. The Department of Health & Human Services' Office for Human Research Protections maintains a database of registered IRBs. Go to <http://ohrp.cit.nih.gov/search/irbsearch.aspx?styp=bsc> and click on "Advanced Search." Enter your state to find registered IRBs in your area.

Contains Nonbinding Recommendations

Draft — Not for Implementation

187 not have an application already filed with FDA, physicians should consult with the
188 relevant review division to determine what information may satisfy the regulatory
189 requirements. For emergency uses, the LOA and other paperwork may be submitted up
190 to 15 working days after the initial authorization.

191
192 *Box 5: Physician's qualification statement* that specifies the medical school attended,
193 year of graduation, medical specialty, state medical license number, current employment,
194 and job title. Alternatively, the portion of the physician's curriculum vitae (usually the
195 first few pages) may be attached, provided it includes the up-to-date information
196 described in this paragraph.

197
198 *Box 6: Physician's name, address, and contact information*, including the physical
199 address, email address, telephone number(s), facsimile number, *and IND number, if*
200 *known*. If the physician has previously communicated with FDA about expanded access
201 for the individual patient, the physician already may have been issued an IND number by
202 FDA staff. If so, the physician should provide that number. Please note that this is NOT
203 the number for the manufacturer's IND to which the physician has obtained an LOA.

204
205 *Box 7: Request for authorization to use Form FDA 3926 for individual patient expanded*
206 *access* to comply with FDA's requirements for submitting an individual patient expanded
207 access IND. Generally, an IND submission includes additional information, beyond that
208 included in draft Form FDA 3926, which may not be necessary for the purposes of
209 submitting an individual patient expanded access IND. Therefore, consistent with 21
210 CFR 312.10, FDA intends to consider a completed draft Form FDA 3926, when
211 finalized, with Box 7 checked, to be a request for a waiver of any additional requirements
212 in 21 CFR part 312. FDA concludes that a waiver of any additional requirements is
213 appropriate for individual patient expanded access INDs because the physician's non-
214 compliance with any such requirements would not pose a significant and unreasonable
215 risk to the individual patient, and the physician's compliance with any such requirements
216 is unnecessary for the Agency to evaluate the IND. Note that as stated in section II.A of
217 this guidance, after the initial submission of draft Form FDA 3926, when finalized, the
218 IND holder (physician) should use Form FDA 1571 for subsequent submissions to the
219 physician IND.

220
221 *Box 8: Certification statement and signature of the physician* certifying that treatment
222 will not begin until 30 days after FDA receives the application unless the submitting
223 physician receives earlier notification from FDA that the treatment may proceed; that the
224 physician will obtain informed consent in compliance with FDA's regulations in 21 CFR
225 part 50; that IRB review of the expanded access use will be obtained in compliance with
226 FDA's regulations in 21 CFR part 56; and that in the case of an emergency request,
227 treatment may begin without prior IRB approval provided the IRB is notified of the
228 emergency treatment within 5 working days of treatment.

187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229

Contains Nonbinding Recommendations

Draft — Not for Implementation

230 After receiving draft Form FDA 3926, when finalized, (i.e., the IND) in a non-emergency
231 situation, FDA will assign an individual IND number to the IND and will either allow the
232 treatment use to proceed or will put the application on clinical hold (see § 312.42). If the
233 treatment use is not allowed to proceed, FDA generally will notify the physician of this decision
234 initially by telephone and will follow up with a written letter that details the reasons for FDA's
235 decision to place the IND on clinical hold. The IND will go into effect (i.e., treatment with the
236 investigational drug may proceed) once FDA notifies the physician or, if no notification occurs,
237 30 days after FDA receives the completed draft Form FDA 3926, when finalized.
238

239 If there is an emergency and authorization of the expanded access use is requested before a
240 written submission can be made, the physician must explain how the expanded access use will
241 meet the criteria of §§ 312.305(a) and 312.310(a), as described previously in Section
242 II. Background. In these situations, treatment with the investigational drug may begin before
243 FDA's receipt of the written submission (including the LOA), but the physician must agree to
244 submit an expanded access submission within 15 working days of FDA's authorization of the
245 expanded access use (§ 312.310(d)). When treatment involves the emergency use of an
246 investigational drug and approval from an IRB cannot be obtained before treatment, treatment
247 may begin without prior IRB approval provided the IRB is notified of the emergency expanded
248 access use within 5 working days of treatment (21 CFR 56.104).
249

250 Secure email between FDA and sponsors is useful for informal communications when
251 confidential information may be included in the message (for example, confidential patient
252 information). Sponsors who would like to establish secure email with FDA should email a
253 request to SecureEmail@fda.hhs.gov.
254

APPENDIX 1: DRAFT FORM FDA 3926

255
256
257 Please see attached appendix for draft FORM FDA 3926.
258

**Individual Patient Expanded Access
Investigational New Drug Application (IND)**
(Title 21, Code of Federal Regulations (CFR) Part 312)

Form Approved: OMB No. xxxx-xxxx
Expiration Date: XXXXXX xx, 201x
See PRA Statement on page 2.

1. Patient's Initials

Date of Submission

2. Clinical Information

Indication

Brief Clinical History *(Patient's age, gender, weight, allergies, diagnosis, prior therapy, response to prior therapy, rationale for request)*

3. Treatment Information

Investigational Drug Name and Manufacturer

FDA Review Division, if known

Treatment Plan *(Including the dose, route of administration, planned duration, and monitoring procedures. Also include modifications to the treatment plan in the event of toxicity.)*

4. Letter of Authorization (LOA), if applicable *(Obtained from manufacturer of the drug)*

I have attached the LOA from the manufacturer. *(Attach the LOA; if electronic, use normal PDF functions for file attachments.)*

I have not attached the LOA. I commit to providing the LOA to FDA.

5. Physician's Qualification Statement *(Including medical school attended, year of graduation, medical specialty, state medical license number, current employment, and job title. Alternatively, attach the first few pages of physician's curriculum vitae (CV), provided they contain this information. (If attaching the CV electronically, use normal PDF functions for file attachments.)*

6. Physician Name, Address and Contact Information

Physician Name (<i>Sponsor</i>)		Email Address of Physician
Address 1 (<i>Street address, No P.O. boxes</i>)		
Address 2 (<i>Apartment, suite, unit, building, floor, etc.</i>)		Telephone Number of Physician
City	State	FAX Number of Physician
ZIP Code		Physician's IND number, if known

7. Request for Authorization to Use Form FDA 3926

- I request authorization to submit this Form FDA 3926, to comply with FDA's requirements for submitting an individual patient expanded access IND. I will use Form FDA 1571 for subsequent submissions to this IND.

8. Certification Statement: I will not begin treatment until 30 days after FDA's receipt of this application unless I receive earlier notification from FDA that treatment may begin. I also certify that I will obtain informed consent, consistent with Federal requirements, and that an Institutional Review Board (IRB) that complies with the Federal IRB requirements will be responsible for initial and continuing review and approval of this treatment use. I understand that in the case of an emergency request, treatment may begin without prior IRB approval, provided the IRB is notified of the emergency treatment within 5 working days of treatment.

Signature of Physician	Date
------------------------	------

For FDA Use Only

IND Number	Is this an emergency individual patient IND? <input type="checkbox"/> Yes <input type="checkbox"/> No	Is this indication for a rare disease (prevalence < 200,000 in the U.S.)? <input type="checkbox"/> Yes <input type="checkbox"/> No
------------	--	---

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 45 minutes per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."